B4GALT1 Knockout jurkat Polyclonal Cells

Product Type:
Polyclonal Cell Population
Species:
Homo sapiens (Human)
Tissue Source:
Blood (peripheral blood)
Disease:
Acute lymphoblastic leukemia (ALL)

Datasheet

CRISPR/Cas9-edited polyclonal knockout cells targeting B4GALT1 in the Jurkat T-lymphoblastoid line. This model ablates the galactosyltransferase responsible for LacNAc synthesis, disrupting glycan-dependent cell adhesion, migration, and immune synapse organization through selectin and galectin pathways. Ideal for investigating glycobiology, tumor metastasis, T-cell signaling, and congenital disorders of glycosylation.

Inquire Now

In stock

Ships next business day

Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice

Disclaimer:

For Research Use Only

Characteristics

Host Cell

Jurkat

Cell Type

T cell line

Sex of Donor

Male

Age

14 years

Derived From Site

In situ; Peripheral blood

Gene Name

B4GALT1

Gene Identifier

NCBI Gene ID 2683

Growth Mode

Suspension

Storage

Liquid nitrogen (LN2)
Culture Conditions

Growth medium

RPMI 1640

Supplement(s)

10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

Temperature

37°C

Atmosphere

5% CO₂
Quality Control

Sterility testing

The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Mycoplasma testing

Negative for mycoplasma through PCR analysis
Disclaimer

Intended Use

This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer

Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

B4GALT1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the B4GALT1 gene has been disrupted to eliminate its glycosyltransferase function.

This product provides a ready-to-use, loss-of-function model derived from the Jurkat T-lymphoblastoid cell line, facilitating the study of galactosylation-dependent processes in a T-cell context.

The polyclonal format preserves population-level heterogeneity while retaining uniform target-gene disruption, making it suitable for experiments where clonal variation is not desired.

Researchers can immediately apply these cells in functional assays to dissect the role of B4GALT1-mediated lactose-derived glycan biosynthesis in immune cell biology and beyond.